TCL Archive Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says. May 7, 2004
TCL Archive In Senate testimony, NCI director uses survival rate as measure of progress for goal to “eliminate suffering and death due to cancer.” July 29, 2005
TCL Archive New Breast Cancer Therapies Move Into General Practice; Fisher, Miami Plan Segmental Trials February 13, 1976
TCL Archive FDA, NCI united in pursuit of 2015 goal, Andrew von Eschenbach tells cancer center directors; says his appointment was necessary to “maintain the momentum of the FDA.” October 21, 2005
TCL Archive DeVita: It Was Time To Go, and The Action Is Hot At Memorial: Says He’ll Work Well With Paul Marks August 19, 1988
